Anthracycline-based chemotherapy remains the standard first-line treatment for unresectable or metastatic liposarcoma, with trabectedin and eribulin as the most promising second-line options.
This review summarizes current and emerging systemic treatments for liposarcoma, highlighting anthracyclines as first-line and trabectedin/eribulin as second-line therapies.
Introduction: Liposarcomas are a heterogeneous group of soft tissue tumors that arise from adipose tissue and are one of the most common soft tissue sarcomas found in adults. Liposarcomas are subclassified into four subtypes with distinct histologic and biologic features that influence their treatment and management.Areas covered: This manuscript reviews the key clinicopathologic and cytogenic characteristics of the liposarcoma histologic subtypes and summarizes the results of recent clinical trials, treatment options, and future directions in the pharmacotherapy for the management of liposarcoma.Expert opinion: Despite significant advancements in the management of this disease, the treatment of liposarcoma continues to be a challenge. Surgical resection remains the mainstay of treatment for localized disease; however, use of systemic therapies in conjunction with surgery may be considered in patients where tumor shrinkage could reduce surgical morbidity and in patients with high-risk of micrometastatic disease. Anthracycline-based chemotherapy regimens remain the standard first-line treatment for unresectable/metastatic liposarcoma. Trabectedin and eribulin are currently the two most promising and evidenced-based second-line treatment options for liposarcomas. However, multiple clinical trials dedicated to patients with liposarcoma evaluating novel targeted agents are ongoing. Every effort should be made to enroll patients with liposarcoma into histotype-specific clinical trials.
Suarez‐Kelly et al. (Tue,) conducted a review in Liposarcoma. Pharmacotherapy (Anthracyclines, Trabectedin, Eribulin) was evaluated. Anthracycline-based chemotherapy remains the standard first-line treatment for unresectable or metastatic liposarcoma, with trabectedin and eribulin as the most promising second-line options.